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S290 Poster Session Irelapse. Five pts have died (median 9 months), 2 from graft-versus-
host disease (GVHD), 2 infections, and 1 elected Hospice care after
experiencing renal failure. Last disease responses were complete re-
mission (n5 8), partial remission (n5 6), stable disease (n5 5), not-
evaluated (n 5 1). The incidences of grades II and III-IV acute
GVHD were 60% and 15% respectively, and chronic GVHD was
46% at 1-year. Estimated 1-year rate of non-relapse mortality
(NRM), relapse, progression-free (PFS), and overall survivals (OS)
were 33%, 0%, 67%, and 67% respectively. Patients receiving
peri-HCT rituximab had lower HR for relapse (HR:0, p 5 0.001),
comparable HR for NRM (HR:1, p 5 0.9) and OS (HR:0.7, p 5
0.45), and a trend for lower HR for PFS (HR:0.5, p 5 0.07)
compared to the historical control group. At day 84, median CD3
chimerisms were 99% vs 95% (p 5 0.08), respectively.
After adjusting for the previous 4 significant covariates, PFS was
better (HR:0.4, p 5 0.04) among the rituximab group. Peri-
transplant rituximab is a promising addition to nonmyeloablative
HCT and may decrease early disease progression by allowing the
generation of potent GVL effects.231
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Leukemic transformation (LT) is a rare but fatal complication of
Philadelphia-negative myeloproliferative neoplasms (MPNs) for
which optimal treatment strategies are not known. LT is generally
considered incurable with induction chemotherapy alone.
At our centre, we have adopted a treatment strategy for LT
where patients within the transplant age group who have a reason-
able fitness level are offered induction therapy. Subsequently, those
who achieve complete remission (CR/CRi) or revert back to
a chronic MPN (cMPN) state are considered eligible for allogeneic
transplantation (allo-SCT) if a suitable related or unrelated donor
is available. Alternatively, those who are not candidates for the
aforementioned strategy are offered supportive therapy including
clinical trials.
We evaluated clinical outcomes of this treatment approach in 75
patients with LT diagnosed between 1998 and 2011. Prior to LT,
MPN diagnoses were: PV, 16%; ET, 16%; primary MF, 28%;
post-PV/ET MF, 25%; and MPN-U, 15%. 39 (52%) patients
were treated with curative intent (induction chemotherapy +/-
allo-SCT) while the remainder were treated with non-curative in-
tent. At the time of LT, the curative intent cohort differed from
the non-curative group in terms of median age (57 vs. 72 yrs,
P\0.0001), performance status (ECOG#1 in 92% vs. 58%, p 5
0.001), serum albumin (38 vs. 35 g/L, p 5 0.008) and the frequency
of normal cytogenetics (47% vs. 20%, p 5 0.03) respectively.
Among all patients, the 2-year overall survival (OS) from the time
of LT was 15%. Outcomes were significantly improved in individ-
uals treated with curative vs. non-curative intent (2-year OS, 25%
vs. 4%, P\ 0.0001). Among the curative group, 30/39 achieved ei-
ther CR (n 5 19) or reversion to cMPN (n 5 11). Suitable donors
were identified for 24 (80%) of these responders and 17 (57%) un-
derwent allo-SCT.Median time to transplant was 177 days. Survival
of patients undergoing allo-SCT was significantly better compared
to those who achievedCR/cMPNpost-induction but were not trans-
planted (2-year OS, 46% (n5 17) vs. 15% (n5 13), P5 0.035). To
avoid a time to transplant bias, a landmark analysis was done compar-
ing survival between the transplant cohort and non-transplanted pa-
tients who survived at least 177 days (n5 13), and similar results were
observed (2-year OS 46% vs. 15%, p 5 0.035).
Our results demonstrate the curative potential of intensive induc-
tion therapy followed by allo-SCT in select patients with LT pre-
ceded by MPN.232
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Background:CAYA with ALL or AML in third complete remission
(CR3), refractory relapse (RR) or induction failure (IF) have an ex-
tremely poor prognosis,\20% EFS (Gaynon, BJH, 2005, Wells et
al, JCO, 2003). MAC prior to AlloSCT is associated with high
TRM and is donor dependent: 5-20% for matched sibling, 10-
40% for matched unrelated, and 20-52% for cord blood transplants.
CLO, an inhibitor of DNA polymerase and ribonucleotide reduc-
tase, has been shown to be safe and induce durable remissions,
both in conjunction with busulfan in poor-risk AML (Magenau et
al., Blood, 2011) and with Melphalan in poor-risk hematologic ma-
lignancies in adults (van Besien et al, ASH,2009). CLO has signifi-
cant activity in CAYA with relapsed ALL/AML (Jeha et al., JCO
2006,2009) and synergy with cytarabine (Faderl et al, Blood,
2005). We sought to determine safety, day-100 TRM, and overall
survival (OS) of CLO, cytarabine and TBI followed by AlloSCT in
CAYA with poor-risk ALL/AML.
Methods: This is an ongoing multi-center phase I/II trial of a novel
conditioning regimen of CLO (dose escalation: 40mg/m2 [n5 3], 46
mg/m2 [n 5 3], 52 mg/m2 [n 5 17]) x5d, sequential (4 hrs later) cy-
tarabine 1000 mg/m2 x6d and TBI (1200cGy) followed by AlloSCT
frommatched related or unrelated donors in CAYA with ALL/AML
in CR3, RR or IF. Pts with unrelated grafts received R-ATG.
GVHDprophylaxis consisted of tacrolimus andMMF (Bhatia/Cairo
et al., BBMT, 2009). Kaplan-Meier method was used to determine
the probabilities of engraftment, GVHD, TRM and OS.
Results: 23 pts, median age: 10.8 yrs (1.5-20.7); M:F: 17:6, ALL/
AML: 20:3 (9 CR3, 3 RR, 11 IF), 9 related donors, 14 unrelated do-
nors (8 BM/PBSCs, 6 UCB). Median TNC and CD34 dose was
4.76x108/kg and 4.84x106/kg for BM/PBSCs and 4.0x107/kg and
2.8x105/kg for UCB, respectively. Probabilities of neutrophil and
platelet engraftment and grade II-IV aGVHD were 100%, 92.8%
and 50.8%, respectively. All except one achieved 100% whole blood
donor chimerism by day 30. CLO dose was tolerable at 52mg/m2/
d x5d without dose limiting toxicity. Probability of Day 100 TRM
was only 5%. Probability of 1-yr PFS and OS were 45% (CI95: 24-
83%), and 44.6% (CI95: 24-68%) respectively.
Conclusions: Preliminary results suggest this novel MAC regimen
followed by AlloSCT is safe and well tolerated in CAYA with
poor-risk ALL/ AML with CLO dose of 52 mg/m2. Early results
are encouraging with respect to low risk of day 100 TRM with this
conditioning regimen in this poor-risk population.233
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There has been a marked change in transplant approaches of the
CLL patient. MA conditioning has been shown to provide high
